Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

Technology appraisal guidance
Reference number: TA333
Published: 25 February 2015

Renal cell carcinoma (advanced) - axitinib: appeal

For more information on the Technology Appraisal Appeal Process, go to the appeal hearings homepage.

This page was last updated: 02 September 2013